Literature DB >> 8768832

Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin.

Y Takeda1, I Miyamori, T Yoneda, H Hatakeyama, S Inaba, K Furukawa, H Mabuchi, R Takeda.   

Abstract

Mineralocorticoids have been suggested to act on blood vessels, leading to increased vasoreactivity and peripheral resistance. Aldosterone is synthesized locally in blood vessels and participates in the hypertrophy of vascular smooth muscle cells. In this study we examined the effects of angiotensin II (ANG II), potassium, and ACTH on the production of aldosterone, the activity of aldosterone synthase, and the expression of CYP11B2 and CYP11B1 messenger ribonucleic acid (mRNA) in cultured human vascular endothelial cells. Human vascular endothelial cells were incubated with ANG II, potassium, or ACTH with or without [14C]deoxycorticosterone ([14C]DOC). Incubation medium was collected, and chromatography was preformed in a reverse phase high performance liquid chromatography system. The concentration of aldosterone in the incubation medium was measured using RIA after separation with the high performance liquid chromatography system. The activity of aldosterone synthase was estimated by the conversion of [14C]DOC to [14C]aldosterone. The levels of CYP11B2 and CYP11B1 mRNA were determined by competitive PCR. ANG II, potassium, and ACTH increased the production levels of aldosterone in a dose-dependent fashion. Both ANG II and potassium increased the conversion of [14C]DOC to [14C]aldosterone, but ACTH did not significantly increase the conversion. Both ANG II and potassium increased the concentration of CYP11B2 mRNA, but not that of CYP11B1 mRNA. Tumor necrosis factor reduced ANG II- and potassium-induced aldosterone synthesis and CYP11B2 mRNA levels. ACTH did not influence the expression of CYP11B2 mRNA. These results suggest that vascular aldosterone synthase is controlled by ANG II and potassium at the transcriptional level.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8768832     DOI: 10.1210/jcem.81.8.8768832

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Aldosterone and vascular damage.

Authors:  D Duprez; M De Buyzere; E R Rietzschel; D L Clement
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 2.  Aldosterone blockade in cardiovascular disease.

Authors:  Allan D Struthers
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

Review 3.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

Review 4.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

5.  [The role of aldosterone in hypertension].

Authors:  Oliver Vonend; Ivo Quack; Lars Christian Rump
Journal:  Wien Klin Wochenschr       Date:  2010-02       Impact factor: 1.704

6.  Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms.

Authors:  Lisa A Cassis; Marc J Helton; Deborah A Howatt; Victoria L King; Alan Daugherty
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

7.  Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways.

Authors:  Alexander W Krug; Lena Allenhöfer; Robert Monticone; Gaia Spinetti; Michael Gekle; Mingyi Wang; Edward G Lakatta
Journal:  Hypertension       Date:  2010-04-26       Impact factor: 10.190

Review 8.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

9.  Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.

Authors:  L J Moran; C Meyer; S K Hutchison; S Zoungas; H J Teede
Journal:  J Endocrinol Invest       Date:  2009-10-15       Impact factor: 4.256

Review 10.  Aldosterone receptor antagonists for hypertension: what do they offer?

Authors:  Danny Liew; Henry Krum
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.